AstraZeneca qualifies outsourcing APIs story
Anglo-Swedish drug major AstraZeneca has denied a recent media report that it plans to outsource all of its Active Pharmaceutical Ingredients (API) production as part of a cost-cutting drive. A spokeswoman for the company told The Pharma Letter that the story goes back three years, when AstraZeneca talked about outsourcing APIs, and this could be to China ' which is seen as an obvious area into which the firm would look, though no decisions have yet been taken.
The story, published in The Times online, stated that the manufacturing shift to Asia could lead to job losses and either plant closures or a sale to another company.
In the UK, Astra makes APIs for cholesterol and schizophrenia drugs in a factory at Avlon, near Bristol, which employs 300 people. An option for that facility could be a sale to a third party but no decision has been taken, an Astra spokesman said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze